IP Library Granted Patent US 7,745,173
Granted Patent B2
US 7,745,173 · App. 12/013,277 · Granted Jun 29, 2010

Histone deacetylase and methods of use thereof

Assignee: The J. David Gladstone Institutes
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,745,173
App. No.
12/013,277
Granted
Jun 29, 2010
Kind
B2
Abstract

The present invention provides nucleic acid molecules that encode histone deacetylase, as well as recombinant vectors and host cells that include the subject nucleic acid molecules. Also provided are histone deacetylase polypeptide compositions. The histone deacteylase nucleic acid molecules are useful in a variety of diagnostic and therapeutic applications, which are also provided.

Claims (18)

1. An in vitro method of identifying an agent that reduces enzymatic activity of histone deacetylase-7 (HDAC-7), the method comprising:

a) contacting an enzymatically active HDAC-7 polypeptide with a test agent, wherein said HDAC-7 polypeptide has at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:02; and

b) determining the effect, if any, of the test agent on enzymatic activity of the HDAC-7 polypeptide.

2. The method according to claim 1 , wherein the HDAC-7 polypeptide is encoded by a nucleic acid present in a eukaryotic expression vector and is expressed in a eukaryotic cell.

3. An in vitro method of identifying an agent that reduces enzymatic activity of histone deacetylase-7 (HDAC-7), the method comprising:

a) contacting an enzymatically active HDAC-7 polypeptide with a test agent, wherein the HDAC-7 polypeptide lacks amino terminal amino acid residues 1-437 of SEQ ID NO:2, and comprises amino acids 438 to 912 of the amino acid sequence set forth in SEQ ID NO:2; and

b) determining the effect, if any, of the test agent on enzymatic activity of the HDAC-7 polypeptide.

4. The method of claim 1 , wherein the HDAC-7 polypeptide is at least 95% pure.

5. The method of claim 1 , wherein the HDAC-7 polypeptide comprises a polypeptide that provides a detectable signal.

6. The method of claim 1 , wherein the candidate agent is an organic compound.

7. The method of claim 1 , wherein the method is a cell-free method.

8. The method of claim 2 , wherein the eukaryotic cell is an immortalized cell line.

9. The method of claim 3 , wherein the HDAC-7 polypeptide is at least 95% pure.

10. The method of claim 3 , wherein the HDAC-7 polypeptide comprises a polypeptide that provides a detectable signal.

11. The method according to claim 3 , wherein the HDAC-7 polypeptide is encoded by a nucleic acid present in a eukaryotic expression vector and is expressed in a eukaryotic cell.

12. The method of claim 3 , wherein the candidate agent is an organic compound.

13. The method of claim 3 , wherein the method is a cell-free method.

14. The method of claim 11 , wherein the eukaryotic cell is an immortalized cell line.

Assignments (3)
CONFIRMATORY LICENSE Recorded May 6, 2010
From: J. DAVID GLADSTONE INSTITUTES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024346/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2008
From: VERDIN, ERIC; FISCHLE, WOLFGANG; DEQUIEDT, FRANCK O.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 021046/0630 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2008
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: THE J. DAVID GLADSTONE INSTITUTES
Reel/Frame 021046/0632 →
Continuity (3)
Division 1017555900 · Jun 17, 2002
Provisional Application 6029922800 · Jun 19, 2001
Related Publication 20080233581A1 · Sep 25, 2008